Industrial Technology Research Institute

Chia-Mu Tu

Chih-Peng Liu

Tsan-Lin Hu

Maggie J M Lu

Min-Ying Lin

Hui-Ping Tsai

Hsiang-Fa Liang

Lain-Tze Lee

Jui-Hsiang Chen

Ming-Cheng Wei

Yi-Hsun Chen

Yuan-Jang Tsai

Yi-Ting Hsieh

Shuen-Hsiang Chou

Hsiang-Wen Tseng

Chun-Min Liu

Ya-Chin Lo

Po-Hung Lai

Yu-Wen Lo

Yen-Fang Wen

Chiu-Lien Hung

Chih-Wei Fu

Tse-Min Teng

Yi-Man Chou

Chia-Wen Huang

Wan-Ru Chen

Ling-Meei Tsay

Li-Syuan Jian

A compound represented by Formula (I), a pharmaceutically acceptable salt or ester, hydrate, solvate or crystalline form thereof is provided: The compound represented by Formula (I) is a &#x3b2;-amino acid derivative, and in Formula (I) X is a single bond or O; Y is NH or C&#x2550;O; Z is C&#x2550;O, C&#x2550;S, NH, W is C or N; A is a single bond, O, OH, OCH, a heterocycle or N; Ris H or F; Ris H, F, OH, CF, CHOH, CHO or Ris H; n is 0 or 1; and m is 0 or 1.

Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase

The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C-Calkane, wherein the modified histidine and the polymer or C-Calkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C-Calkane is about 0-40%.

Biomedical composition

The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Pharmaceutical composition

The disclosure is directed to a monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, possessing diffraction peaks of about 12.9&#xb0;, 15.9&#xb0;, 17.9&#xb0;, 21.2&#xb0;, 22.9&#xb0;, 23.5&#xb0; and 24.5&#xb0;. Its preparation method and pharmaceutical composition thereof are also provided.

Monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)-piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, preparation, and pharmaceutical composition thereof

A composition used for skin whitening includes: an effective amount of spermidine derivative, wherein a structure of the spermidine derivative is shown as Structure (I): where R1-R5 individually includes H, OH, or OCHand at least one of R1-R5 is OH, and the spermidine derivative has tyrosinase inhibition activity; and a cosmetically or pharmaceutically acceptable vehicle, wherein the composition used for skin whitening whitens skin.

Composition used for skin whitening, plant extracted skin whitening composition and composition having a skin whitening effect

Growing community of inventors

Taipei, Taiwan

Chia-Mu Tu